David Vercel
Family · Tucson, AZNPI 1225687023
Payments from drug & device makers
Across 64 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$307
- AbbVie$114
- GSK$95
- Sunovion Pharmaceuticals Inc.$52
- Paratek Pharmaceuticals, Inc.$51
- Sanofi-aventis U.S. LLC$48
- plus $459 from 18 others
What the payments were for
- Food & beverage$1,10698%
- Entertainment$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $307 |
| AbbVie | 7 | $114 |
| GSK | 6 | $95 |
| Sunovion Pharmaceuticals Inc. | 2 | $52 |
| Paratek Pharmaceuticals, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Astellas Pharma US Inc | 3 | $41 |
| Novartis | 2 | $38 |
| Sanofi Pasteur Inc. | 2 | $38 |
| Boehringer Ingelheim | 1 | $34 |
| Novo Nordisk | 2 | $32 |
| Idorsia Pharmaceuticals US Inc | 2 | $30 |
| Johnson & Johnson | 2 | $27 |
| Pfizer | 2 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Amgen | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Optos, Inc. | 1 | $19 |
| Exact Sciences | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Bayer | 1 | $16 |
| Merck | 1 | $14 |
How this compares
$1,125 in reported general payments places this provider in the 70th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 70 | $85,269 |
| OzempicSemaglutide | 51 | $65,639 |
| JardianceEmpagliflozin | 21 | $34,651 |
| EliquisApixaban | 25 | $31,130 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $21,660 |
| FarxigaDapagliflozin Propanediol | 13 | $19,733 |
| MyrbetriqMirabegron | 18 | $17,578 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $6,172 |
| Arnuity ElliptaFluticasone Furoate | 20 | $6,161 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 115 | $2,383 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $2,050 |
| Gabapentin | 105 | $1,990 |
| Famotidine | 44 | $1,718 |
| Atorvastatin Calcium | 226 | $1,442 |
| Omeprazole | 85 | $1,418 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $17 | $85,26970 claims |
| Novo NordiskOzempic | $32 | $65,63951 claims |
| Boehringer IngelheimJardiance | $34 | $34,65121 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Arnuity Ellipta | $95 | $33,99368 claims |
| PfizerEliquis | $26 | $31,13025 claims |
| AstraZenecaFarxiga | $307 | $19,73313 claims |
| Astellas Pharma US IncMyrbetriq | $41 | $17,57818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,119 family providers in Arizona.
Other family in Tucson
- Lindsay CarterTucson$108K
- Vicki McIntyreTucson$68K
- Amber KemnitzTucson$33K
- Joy BaynesTucson$30K
- Cynthia CarstenTucson$27K
- Sharon MorganTucson$22K
- Margaret SpencerTucson$19K
- Polina SamoylovaTucson$18K
- Stephanie Niemi-OlsonTucson$15K
- Cindy ChangTucson$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.